Natco Pharma Ltd. has reported a significant decline in its financial performance for Q3 FY25, with a sharp drop in revenue, net profit, and EBITDA margins.
Key Financial Highlights (Q3 FY25 vs Q3 FY24):
- Revenue: ₹475 crore (▼37.4% YoY from ₹759 crore)
- Net Profit (PAT): ₹132.4 crore (▼37.8% YoY from ₹212.7 crore)
- EBITDA: ₹38.8 crore (▼85.5% YoY from ₹268.1 crore)
- EBITDA Margin: 8.2% (▼2717 bps YoY from 35.3%)
Performance Overview:
The sharp decline in revenue and profit was driven by weaker operational performance and increased expenses. The steep drop in EBITDA margin reflects cost pressures and reduced efficiency in operations.
Market Reaction & Outlook:
- The stock reacted negatively to the earnings report, with investors expressing concerns over declining margins.
- Natco Pharma’s focus on expanding its specialty pharma business and niche products will be key to reviving growth in the upcoming quarters.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
TOPICS:
Natco Pharma